Metraipolis › archive › dc_a4e25de03fdf

Risk of Incident Immune-Mediated Inflammatory Diseases with Second Tumor Necrosis Factor Inhibitor Versus Alternative Biologic Therapy in Patients with… — Europe PMC PMID:41364352

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/41364352
DOI: 10.1007/s10620-[numero omesso]-4
License (as archived): solo-consultazione
Archived: 2026-11-07T18:50:18.258Z
SHA-256 of the archived text: 16ef06940e38a79198afcdde78f89c99a09d230ae97f6409d9106eab0a391c60
Stable URL of this page: https://metraipolis.com/documento/dc_a4e25de03fdf

How to cite

Risk of Incident Immune-Mediated Inflammatory Diseases with Second Tumor Necrosis Factor Inhibitor Versus Alternative Biologic Therapy in Patients with… — Europe PMC PMID:41364352 — Europe PMC (en), https://europepmc.org/article/MED/41364352 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_a4e25de03fdf (Metraipolis archive dc_a4e25de03fdf, sha256 16ef06940e38a79198afcdde78f89c99a09d230ae97f6409d9106eab0a391c60)

BibTeX

@misc{dca4e25de03fdf,
  title = {Risk of Incident Immune-Mediated Inflammatory Diseases with Second Tumor Necrosis Factor Inhibitor Versus Alternative Biologic Therapy in Patients with… — Europe PMC PMID:41364352},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41364352},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_a4e25de03fdf; sha256 16ef06940e38a79198afcdde78f89c99a09d230ae97f6409d9106eab0a391c60},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41364352. Agents can read the archived copy with the MCP tool read_document.